Review
PDF EndNote BibTex RIS Cite

Year 2021, Volume 38, Issue 3, 361 - 366, 01.05.2021

Abstract

References

  • Ankrum, J., Karp, J.M., 2010. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends. Mol. Med. 16, 203-9.
  • Artini, P.G., et al., 1996. Growth hormone cotreatment with gonadotropins in ovulation induction. J. Endocrinol. Invest. 19, 763-779.
  • Augello, A., et al., 2005. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35, 1482-1490.
  • Badawy, A., Elnashar, A., 2011. Treatment options for polycystic ovary syndrome. Int. J. Women's Health. 3, 25.
  • Boostanfar, R., et al., 2001. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil. Steril. 75, 1024-1026.
  • Corbould, A., 2008. Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: Are the molecular mechanisms distinct from type 2 diabetes? Panminerva Med. 50, 279-294.
  • Demyda, S., Genero, E., 2011. Developmental competence of in vivo and in vitro matured oocytes: A review. Biotechnol. Mol. Biol. 6, 155-165.
  • Ding, D.-C., et al., 2011. Mesenchymal stem cells. Cell Transplant. 20, 5-14.
  • Divyashree, S., et al., 2019. Experimental models of polycystic ovary syndrome: An update. Life Sci. 237, 116911.
  • Dominici, M., et al., 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 8, 315-317.
  • Ellenbogen, A., et al., 2014. Ivm results are comparable and may have advantages over standard ivf. Facts Views Vis. Obgyn. 6, 77.
  • Elnashar, A., et al., 2006. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: A prospective placebo-controlled study. Hum. Reprod. 21, 1805-1808.
  • Franks, S., et al., 2008. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum. Reprod. Update. 14, 367-378.
  • He, Y., et al., 2018. The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure. Stem Cell Res. Ther. 9, 263.
  • Hernigou, P., et al., 1997. Bone-marrow transplantation in sickle-cell disease. Effect on osteonecrosis: A case report with a four-year follow-up. JBJS. 79, 1726-30.
  • Huang, X., et al., 2013. Differences in the transcriptional profiles of human cumulus cells isolated from mi and mii oocytes of patients with polycystic ovary syndrome. Reprod. (Cambridge, England). 145, 597-608.
  • Hwu, Y., et al., 2005. Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. Int. J. Gynecol. Obstet. 90, 39-43.
  • Ishizuka, Y., et al., 2013. The influence of reduced glutathione in fertilization medium on the fertility of in vitro–matured c57bl/6 mouse oocytes. Theriogenology. 80, 421-426.
  • Jafarzadeh, H., et al., 2018. Improvement of oocyte in vitro maturation from mice with polycystic ovary syndrome by human mesenchymal stromal cell–conditioned media. J. Cell. Biochem. 119, 10365-10375.
  • Jee, B.C., et al., 2008. Influence of well defined protein source on in vitro maturation of human oocyte: Human follicular fluid versus human serum albumin. Fertil. Steril. 89, 348-352.
  • Kalhori, Z., et al., 2018. Improvement of the folliculogenesis by transplantation of bone marrow mesenchymal stromal cells in mice with induced polycystic ovary syndrome. Cytotherapy. 20, 1445-1458.
  • Legro, R.S., et al., 2007. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 356, 551-566.
  • Li, J., et al., 2015. Estrogen secreted by mesenchymal stem cells necessarily determines their feasibility of therapeutical application. Sci. Rep. 5, 15286.
  • Lim, K.S., et al., 2013. In vitro maturation: Clinical applications. Clin. Exp. Reprod. Med. 40, 143.
  • Lin, C.-Y., et al., 2011. The role of adipose-derived stem cells engineered with the persistently expressing hybrid baculovirus in the healing of massive bone defects. Biomaterials. 32, 6505-6514.
  • Ling, B., et al., 2008. Effect of conditioned medium of mesenchymal stem cells on the in vitro maturation and subsequent development of mouse oocyte. Braz. J. Med. Biol. Res. 41, 978-985.
  • Lizneva, D., et al., 2016. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil. Steril. 106, 6-15.
  • Lou, G., et al., 2015. Exosomes derived from mir-122-modified adipose tissue-derived mscs increase chemosensitivity of hepatocellular carcinoma. J. Hematol. Oncol. 8, 1-11.
  • Messinis, I., Nillius, S., 1982. Comparison between tamoxifen and clomiphene for induction of ovulation. Acta Obstet. Gynecol. Scand. 61, 377.
  • Mutlu, L., et al., 2015. The endometrium as a source of mesenchymal stem cells for regenerative medicine. Biol. Reprod. 92,.
  • Nardo, L., 2004. Management of anovulatory infertility associated with polycystic ovary syndrome: Tamoxifen citrate an effective alternative compound to clomiphene citrate. Gynecol. Endocrinol. 19, 235-238.
  • Parsanezhad, M.E., et al., 2002. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: A prospective, double-blind, placebo-controlled trial. Fertil. Steril. 78, 1001-1004.
  • Qu, Y., et al., 2017. Exosomes derived from mir‐181‐5p‐modified adipose‐derived mesenchymal stem cells prevent liver fibrosis via autophagy activation. J. Cell. Mol. Med. 21, 2491-2502.
  • Sam, S., Dunaif, A., 2003. Polycystic ovary syndrome: Syndrome. Trends Endrocrinol. Metab. 14, 365-370.
  • Sánchez, F., et al., 2015. Human cumulus-enclosed germinal vesicle oocytes from early antral follicles reveal heterogeneous cellular and molecular features associated with in vitro maturation capacity. Hum. Reprod. 30, 1396-1409.
  • Shalom-Paz, E., et al., 2012. Pcos patients can benefit from in vitro maturation (ivm) of oocytes. Eur. J. Obstet. Gynecol. Reprod. Biol. 165, 53-56.
  • Stein, I.F., 1935. Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29, 181-191.
  • Stener-Victorin, E., et al., 2000. Effects of electro-acupuncture on anovulation in women with polycystic ovary syndrome. Acta Obstet. Gynecol. Scand. 79, 180-188.
  • Teede, H., et al., 2010. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8, 41.
  • Wang, T., et al., 2019. Mir-323-3p regulates the steroidogenesis and cell apoptosis in polycystic ovary syndrome (PCOS) by targeting igf-1. Gene. 683, 87-100.
  • Xie, Q., et al., 2019. Mesenchymal stem cells alleviate dhea-induced polycystic ovary syndrome (PCOS) by inhibiting inflammation in mice. Stem Cells Int. 2019,.
  • Xin, H., et al., 2012. Exosome‐mediated transfer of mir‐133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 30, 1556-1564.
  • Yeo, R.W.Y., et al., 2013. Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev. 65, 336-341.
  • Yildiz, B.O., et al., 2012. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. 27, 3067-3073.
  • Yoon, B.S., et al., 2010. Secretory profiles and wound healing effects of human amniotic fluid–derived mesenchymal stem cells. Stem Cells Dev. 19, 887-902.
  • Zhang, X., et al., 2015. Exosomes in cancer: Small particle, big player. J. Hematol. Oncol. 8, 83.
  • Zhao, Y., et al., 2019. Mesenchymal stem cells derived exosomal mir-323-3p promotes proliferation and inhibits apoptosis of cumulus cells in polycystic ovary syndrome (PCOS). Artif. Cells Nanomed. Biotechnol. 47, 3804-3813.
  • Zomer, A., et al., 2010. Exosomes: Fit to deliver small RNA. Commun. Integr. Biol. 3, 447-450.

Mesenchymal stem cell applications in polycystic ovary syndrome treatment

Year 2021, Volume 38, Issue 3, 361 - 366, 01.05.2021

Abstract

Mesenchymal stem cells (MSCs) are highly capable of self-renewal and differentiation. They can be isolated from a variety of sources such as adipose tissue, bone marrow, umbilical cord, tooth pulp and can be cultured under in vitro conditions. MSCs have anti-inflammatory, anti-apoptotic, angiogenic, immunomodulatory and many more therapeutic effects due to the effects of paracrine factors they secrete. Today, mesenchymal stem cells are used for treatment in more than twenty diseases, from spinal cord injuries to diabetes. However, there is little mention in the literature of the use of these cells in female reproductive system diseases. In this review, a limited number of clinical and experimental studies on the use of mesenchymal stem cells in the treatment of polycystic ovary syndrome, which is very common in women, were examined and analyzed.

References

  • Ankrum, J., Karp, J.M., 2010. Mesenchymal stem cell therapy: Two steps forward, one step back. Trends. Mol. Med. 16, 203-9.
  • Artini, P.G., et al., 1996. Growth hormone cotreatment with gonadotropins in ovulation induction. J. Endocrinol. Invest. 19, 763-779.
  • Augello, A., et al., 2005. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35, 1482-1490.
  • Badawy, A., Elnashar, A., 2011. Treatment options for polycystic ovary syndrome. Int. J. Women's Health. 3, 25.
  • Boostanfar, R., et al., 2001. A prospective randomized trial comparing clomiphene citrate with tamoxifen citrate for ovulation induction. Fertil. Steril. 75, 1024-1026.
  • Corbould, A., 2008. Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: Are the molecular mechanisms distinct from type 2 diabetes? Panminerva Med. 50, 279-294.
  • Demyda, S., Genero, E., 2011. Developmental competence of in vivo and in vitro matured oocytes: A review. Biotechnol. Mol. Biol. 6, 155-165.
  • Ding, D.-C., et al., 2011. Mesenchymal stem cells. Cell Transplant. 20, 5-14.
  • Divyashree, S., et al., 2019. Experimental models of polycystic ovary syndrome: An update. Life Sci. 237, 116911.
  • Dominici, M., et al., 2006. Minimal criteria for defining multipotent mesenchymal stromal cells. The international society for cellular therapy position statement. Cytotherapy. 8, 315-317.
  • Ellenbogen, A., et al., 2014. Ivm results are comparable and may have advantages over standard ivf. Facts Views Vis. Obgyn. 6, 77.
  • Elnashar, A., et al., 2006. Clomiphene citrate and dexamethazone in treatment of clomiphene citrate-resistant polycystic ovary syndrome: A prospective placebo-controlled study. Hum. Reprod. 21, 1805-1808.
  • Franks, S., et al., 2008. Follicle dynamics and anovulation in polycystic ovary syndrome. Hum. Reprod. Update. 14, 367-378.
  • He, Y., et al., 2018. The therapeutic potential of bone marrow mesenchymal stem cells in premature ovarian failure. Stem Cell Res. Ther. 9, 263.
  • Hernigou, P., et al., 1997. Bone-marrow transplantation in sickle-cell disease. Effect on osteonecrosis: A case report with a four-year follow-up. JBJS. 79, 1726-30.
  • Huang, X., et al., 2013. Differences in the transcriptional profiles of human cumulus cells isolated from mi and mii oocytes of patients with polycystic ovary syndrome. Reprod. (Cambridge, England). 145, 597-608.
  • Hwu, Y., et al., 2005. Ultra-short metformin pretreatment for clomiphene citrate-resistant polycystic ovary syndrome. Int. J. Gynecol. Obstet. 90, 39-43.
  • Ishizuka, Y., et al., 2013. The influence of reduced glutathione in fertilization medium on the fertility of in vitro–matured c57bl/6 mouse oocytes. Theriogenology. 80, 421-426.
  • Jafarzadeh, H., et al., 2018. Improvement of oocyte in vitro maturation from mice with polycystic ovary syndrome by human mesenchymal stromal cell–conditioned media. J. Cell. Biochem. 119, 10365-10375.
  • Jee, B.C., et al., 2008. Influence of well defined protein source on in vitro maturation of human oocyte: Human follicular fluid versus human serum albumin. Fertil. Steril. 89, 348-352.
  • Kalhori, Z., et al., 2018. Improvement of the folliculogenesis by transplantation of bone marrow mesenchymal stromal cells in mice with induced polycystic ovary syndrome. Cytotherapy. 20, 1445-1458.
  • Legro, R.S., et al., 2007. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N. Engl. J. Med. 356, 551-566.
  • Li, J., et al., 2015. Estrogen secreted by mesenchymal stem cells necessarily determines their feasibility of therapeutical application. Sci. Rep. 5, 15286.
  • Lim, K.S., et al., 2013. In vitro maturation: Clinical applications. Clin. Exp. Reprod. Med. 40, 143.
  • Lin, C.-Y., et al., 2011. The role of adipose-derived stem cells engineered with the persistently expressing hybrid baculovirus in the healing of massive bone defects. Biomaterials. 32, 6505-6514.
  • Ling, B., et al., 2008. Effect of conditioned medium of mesenchymal stem cells on the in vitro maturation and subsequent development of mouse oocyte. Braz. J. Med. Biol. Res. 41, 978-985.
  • Lizneva, D., et al., 2016. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil. Steril. 106, 6-15.
  • Lou, G., et al., 2015. Exosomes derived from mir-122-modified adipose tissue-derived mscs increase chemosensitivity of hepatocellular carcinoma. J. Hematol. Oncol. 8, 1-11.
  • Messinis, I., Nillius, S., 1982. Comparison between tamoxifen and clomiphene for induction of ovulation. Acta Obstet. Gynecol. Scand. 61, 377.
  • Mutlu, L., et al., 2015. The endometrium as a source of mesenchymal stem cells for regenerative medicine. Biol. Reprod. 92,.
  • Nardo, L., 2004. Management of anovulatory infertility associated with polycystic ovary syndrome: Tamoxifen citrate an effective alternative compound to clomiphene citrate. Gynecol. Endocrinol. 19, 235-238.
  • Parsanezhad, M.E., et al., 2002. Use of dexamethasone and clomiphene citrate in the treatment of clomiphene citrate-resistant patients with polycystic ovary syndrome and normal dehydroepiandrosterone sulfate levels: A prospective, double-blind, placebo-controlled trial. Fertil. Steril. 78, 1001-1004.
  • Qu, Y., et al., 2017. Exosomes derived from mir‐181‐5p‐modified adipose‐derived mesenchymal stem cells prevent liver fibrosis via autophagy activation. J. Cell. Mol. Med. 21, 2491-2502.
  • Sam, S., Dunaif, A., 2003. Polycystic ovary syndrome: Syndrome. Trends Endrocrinol. Metab. 14, 365-370.
  • Sánchez, F., et al., 2015. Human cumulus-enclosed germinal vesicle oocytes from early antral follicles reveal heterogeneous cellular and molecular features associated with in vitro maturation capacity. Hum. Reprod. 30, 1396-1409.
  • Shalom-Paz, E., et al., 2012. Pcos patients can benefit from in vitro maturation (ivm) of oocytes. Eur. J. Obstet. Gynecol. Reprod. Biol. 165, 53-56.
  • Stein, I.F., 1935. Amenorrhea associated with bilateral polycystic ovaries. Am. J. Obstet. Gynecol. 29, 181-191.
  • Stener-Victorin, E., et al., 2000. Effects of electro-acupuncture on anovulation in women with polycystic ovary syndrome. Acta Obstet. Gynecol. Scand. 79, 180-188.
  • Teede, H., et al., 2010. Polycystic ovary syndrome: A complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med. 8, 41.
  • Wang, T., et al., 2019. Mir-323-3p regulates the steroidogenesis and cell apoptosis in polycystic ovary syndrome (PCOS) by targeting igf-1. Gene. 683, 87-100.
  • Xie, Q., et al., 2019. Mesenchymal stem cells alleviate dhea-induced polycystic ovary syndrome (PCOS) by inhibiting inflammation in mice. Stem Cells Int. 2019,.
  • Xin, H., et al., 2012. Exosome‐mediated transfer of mir‐133b from multipotent mesenchymal stromal cells to neural cells contributes to neurite outgrowth. Stem Cells. 30, 1556-1564.
  • Yeo, R.W.Y., et al., 2013. Mesenchymal stem cell: An efficient mass producer of exosomes for drug delivery. Adv. Drug Deliv. Rev. 65, 336-341.
  • Yildiz, B.O., et al., 2012. Prevalence, phenotype and cardiometabolic risk of polycystic ovary syndrome under different diagnostic criteria. Hum. Reprod. 27, 3067-3073.
  • Yoon, B.S., et al., 2010. Secretory profiles and wound healing effects of human amniotic fluid–derived mesenchymal stem cells. Stem Cells Dev. 19, 887-902.
  • Zhang, X., et al., 2015. Exosomes in cancer: Small particle, big player. J. Hematol. Oncol. 8, 83.
  • Zhao, Y., et al., 2019. Mesenchymal stem cells derived exosomal mir-323-3p promotes proliferation and inhibits apoptosis of cumulus cells in polycystic ovary syndrome (PCOS). Artif. Cells Nanomed. Biotechnol. 47, 3804-3813.
  • Zomer, A., et al., 2010. Exosomes: Fit to deliver small RNA. Commun. Integr. Biol. 3, 447-450.

Details

Primary Language English
Subjects Health Care Sciences and Services
Journal Section Clinical Research
Authors

Muhammet Volkan BÜLBÜL> (Primary Author)
İSTANBUL MEDİPOL ÜNİVERSİTESİ
0000-0003-1526-2065
Türkiye


Berna YILDIRIM>
İSTANBUL MEDİPOL ÜNİVERSİTESİ
0000-0002-4479-2586
Türkiye


Bircan KOLBAŞI>
İSTANBUL MEDİPOL ÜNİVERSİTESİ
0000-0001-7933-4262
Türkiye


İlknur KESKİN>
İSTANBUL MEDİPOL ÜNİVERSİTESİ
0000-0002-7059-1884
Türkiye

Publication Date May 1, 2021
Application Date November 14, 2020
Acceptance Date December 16, 2020
Published in Issue Year 2021, Volume 38, Issue 3

Cite

Bibtex @review { omujecm825834, journal = {Journal of Experimental and Clinical Medicine}, issn = {1309-4483}, eissn = {1309-5129}, address = {}, publisher = {Ondokuz Mayıs University}, year = {2021}, volume = {38}, number = {3}, pages = {361 - 366}, title = {Mesenchymal stem cell applications in polycystic ovary syndrome treatment}, key = {cite}, author = {Bülbül, Muhammet Volkan and Yıldırım, Berna and Kolbaşı, Bircan and Keskin, İlknur} }
APA Bülbül, M. V. , Yıldırım, B. , Kolbaşı, B. & Keskin, İ. (2021). Mesenchymal stem cell applications in polycystic ovary syndrome treatment . Journal of Experimental and Clinical Medicine , 38 (3) , 361-366 . Retrieved from https://dergipark.org.tr/en/pub/omujecm/issue/62209/825834
MLA Bülbül, M. V. , Yıldırım, B. , Kolbaşı, B. , Keskin, İ. "Mesenchymal stem cell applications in polycystic ovary syndrome treatment" . Journal of Experimental and Clinical Medicine 38 (2021 ): 361-366 <https://dergipark.org.tr/en/pub/omujecm/issue/62209/825834>
Chicago Bülbül, M. V. , Yıldırım, B. , Kolbaşı, B. , Keskin, İ. "Mesenchymal stem cell applications in polycystic ovary syndrome treatment". Journal of Experimental and Clinical Medicine 38 (2021 ): 361-366
RIS TY - JOUR T1 - Mesenchymal stem cell applications in polycystic ovary syndrome treatment AU - Muhammet VolkanBülbül, BernaYıldırım, BircanKolbaşı, İlknurKeskin Y1 - 2021 PY - 2021 N1 - DO - T2 - Journal of Experimental and Clinical Medicine JF - Journal JO - JOR SP - 361 EP - 366 VL - 38 IS - 3 SN - 1309-4483-1309-5129 M3 - UR - Y2 - 2020 ER -
EndNote %0 Journal of Experimental and Clinical Medicine Mesenchymal stem cell applications in polycystic ovary syndrome treatment %A Muhammet Volkan Bülbül , Berna Yıldırım , Bircan Kolbaşı , İlknur Keskin %T Mesenchymal stem cell applications in polycystic ovary syndrome treatment %D 2021 %J Journal of Experimental and Clinical Medicine %P 1309-4483-1309-5129 %V 38 %N 3 %R %U
ISNAD Bülbül, Muhammet Volkan , Yıldırım, Berna , Kolbaşı, Bircan , Keskin, İlknur . "Mesenchymal stem cell applications in polycystic ovary syndrome treatment". Journal of Experimental and Clinical Medicine 38 / 3 (May 2021): 361-366 .
AMA Bülbül M. V. , Yıldırım B. , Kolbaşı B. , Keskin İ. Mesenchymal stem cell applications in polycystic ovary syndrome treatment. J. Exp. Clin. Med.. 2021; 38(3): 361-366.
Vancouver Bülbül M. V. , Yıldırım B. , Kolbaşı B. , Keskin İ. Mesenchymal stem cell applications in polycystic ovary syndrome treatment. Journal of Experimental and Clinical Medicine. 2021; 38(3): 361-366.
IEEE M. V. Bülbül , B. Yıldırım , B. Kolbaşı and İ. Keskin , "Mesenchymal stem cell applications in polycystic ovary syndrome treatment", Journal of Experimental and Clinical Medicine, vol. 38, no. 3, pp. 361-366, May. 2021